Paperonium

Melanoma surgery · N Engl J Med · 2014

Promised goal: do patients live longer? Paper’s goal: melanoma deaths only. The switch is never mentioned.

The public plan2006 to 2015, same in every versionThe paper2014Main goalMissingLiving longerdeaths from any causeMelanoma deathsMelanoma deathsin no versionLiving longernever mentioned
The public plan2006 to 2015, samein every versionThe paper2014Main goalMissingLiving longerdeaths fromany causeMelanoma deathsMelanoma deathsin no versionLiving longernever mentioned

The trial’s main goal: as publicly promised, and as used in the paper

The paper says

A 2,001-patient melanoma trial tested an extra operation: removing the lymph nodes cancer spreads to first. The paper’s main goal: melanoma deaths. Its main group showed no clear difference: 0.84 times as likely with the extra operation, anywhere from 0.64 (fewer deaths) to 1.09 (more).

Its own data show

The trial’s entry on ClinicalTrials.gov, a public registry, was filed in 2006 and updated 9 times through 2015. Every version names one main goal: do patients live longer, counting deaths from any cause? None lists melanoma deaths alone as any goal. The paper never mentions this goal and gives no result for it.

Trials publicly post their main goal, the result they’ll be judged on, so it can’t be swapped later. This entry came late, 12 years into the trial, but still 8 years before the paper. Counting only melanoma deaths leaves out deaths from other causes, so it can’t answer the promised question: did the operation change how long patients lived?

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma · N Engl J Med (2014) · doi:10.1056/NEJMoa1310460